Related Experiment Videos
Immunohistochemical study of the distribution of intercellular adhesion molecule-1 and lymphocyte function-associated
1First Department of Internal Medicine, Okayama University Medical School, Japan.
Insights
In chronic hepatitis B, intercellular adhesion molecule-1 (ICAM-1) expression on liver cells increases with inflammation severity. This pathway, involving lymphocyte function-associated antigen-1 (LFA-1), contributes to liver cell damage.
Area of Science:
- Immunology
- Hepatology
- Cell Biology
Background:
- Chronic hepatitis B (CHB) involves liver inflammation and damage.
- Adhesion molecules play roles in immune cell trafficking and tissue injury.
Purpose of the Study:
- To investigate the expression and role of ICAM-1 and LFA-1 in liver tissue from CHB patients.
- To correlate ICAM-1/LFA-1 expression with liver inflammation severity and HBV levels.
Main Methods:
- Immunohistochemistry using light and electron microscopy on liver biopsies from 11 CHB patients.
- Assessment of ICAM-1 and LFA-1 expression on hepatocytes and infiltrating lymphocytes.
- Correlation with HLA class 1 antigen expression and HBV quantification.
Main Results:
- ICAM-1 expression on hepatocytes shifted from canalicular to diffuse with increasing inflammation.
- Severe inflammation showed diffuse ICAM-1 on hepatocytes and LFA-1 positive lymphocytes invading liver tissue.
- Diffuse ICAM-1 and HLA class 1 antigen expression correlated with decreased HBV levels, particularly after acute exacerbations.
Conclusions:
- The ICAM-1/LFA-1 pathway is implicated in the immune-mediated liver cell damage observed in CHB.
- ICAM-1 expression patterns reflect inflammation severity and may be linked to viral load reduction.
Abstract:
The expression of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) in the livers of 11 patients with chronic hepatitis B was studied immunohistochemically by light and electron microscopy to clarify the role of these adhesion molecules in tissue damage in chronic hepatitis B. On hepatocytes, ICAM-1 expression was confined to the bile canalicular surface when the liver inflammation was mild. In contrast, when the liver inflammation was severe, ICAM-1 was distributed on the entire surface of the hepatocyte, including the sinusoidal and lateral membranes; lymphocytes which were mostly positive for LFA-1, were often observed invading deeply among these hepatocytes. The degree of ICAM-1 expression on the hepatocytes was also related to the expression of HLA class 1 antigen. In liver showing diffuse expression of ICAM-1 on the hepatocytes, strong expression of HLA class 1 antigen was observed, and amounts of HBV in the liver were decreased. Diffuse expression of ICAM-1 and HLA class 1 antigen was mostly observed after acute exacerbation of liver inflammation. These results suggest that the ICAM-1/LFA-1 pathway is involved in the immunological mechanism responsible for liver cell damage in chronic hepatitis B.